Inhibikase Therapeutics Valuation
Is IQT0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IQT0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IQT0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IQT0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IQT0?
Key metric: As IQT0 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is IQT0's PB Ratio? | |
|---|---|
| PB Ratio | -254.5x |
| Book | -US$530.59k |
| Market Cap | US$135.06m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 132030291x |
| Enterprise Value/EBITDA | -6.6x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does IQT0's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.3x | ||
VSC 4SC | 44x | n/a | €49.1m |
HPHA Heidelberg Pharma | 2.9x | -33.0% | €103.9m |
MDG1 Medigene | 1.2x | -4.1% | €22.6m |
2INV 2invest | 1x | n/a | €63.8m |
IQT0 Inhibikase Therapeutics | n/a | 7.5% | €135.1m |
Price-To-Book vs Peers: IQT0 has negative equity and a Price-To-Book Ratio (-254.5x) compared to the peer average (12.5x).
Price to Book Ratio vs Industry
How does IQT0's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: IQT0 has negative equity and a Price-To-Book Ratio (-254.5x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is IQT0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -254.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate IQT0's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €6.66 0% | 20.2% | €7.61 | €4.76 | n/a | 3 |
| Nov ’25 | €2.50 | €5.94 +137.8% | 23.1% | €7.32 | €4.57 | n/a | 2 |
| Oct ’25 | €1.10 | €10.48 +852.6% | 30.4% | €13.67 | €7.29 | n/a | 2 |
| Sep ’25 | €1.26 | €10.48 +731.7% | 30.4% | €13.67 | €7.29 | n/a | 2 |
| Aug ’25 | €1.36 | €14.44 +962.0% | 48.4% | €21.43 | €7.45 | n/a | 2 |
| Jul ’25 | €1.18 | €14.44 +1,124.0% | 48.4% | €21.43 | €7.45 | n/a | 2 |
| Jun ’25 | €1.68 | €14.28 +749.9% | 48.4% | €21.19 | €7.37 | n/a | 2 |
| May ’25 | €1.55 | €16.29 +951.1% | 54.3% | €25.14 | €7.45 | n/a | 2 |
| Apr ’25 | €2.04 | €16.29 +698.8% | 54.3% | €25.14 | €7.45 | n/a | 2 |
| Mar ’25 | €2.03 | €16.19 +698.4% | 54.3% | €24.98 | €7.40 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$705.00
7D
-7.1%
1Y
-3.8%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-6.2%
1Y
90.0%
Merck
US$246.5b
Operates as a healthcare company worldwide.
6MK
US$93.40
7D
0.3%
1Y
-0.4%